Praxis Precision Medicines is a clinical-stage biopharmaceutical company developing therapies for central nervous system disorders. It applies a precision-medicine approach, including genetically informed drug design, to conditions such as epilepsy and other neurological and psychiatric diseases. Its pipeline centers on small-molecule and antisense candidates rather than commercial products, reflecting an R&D-focused model aimed at hard-to-treat CNS indications.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 0 | — | -69.3 | — |
| Q2 2025 | 0 | — | -71.1 | — |
| Q3 2025 | 0 | — | -73.9 | — |
| Q4 2025 | 0 | — | -88.9 | — |
| Q1 2026 | 0 | — | -92.6 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Kymera Therapeutics, Inc. (KYMR), ABIVAX Société Anonyme (ABVX), Zions Bancorporation, National Association (ZION), Hut 8 Corp. (HUT), Kratos Defense & Security Solutions, Inc. (KTOS), Protagonist Therapeutics, Inc. (PTGX)